Brief: Exelixis And Insilico Medicine Enter Into Agreement For ISM3091
12/09/2023 14:18
Sept 12 (Reuters) - Exelixis Inc EXEL.O :
* EXELIXIS AND INSILICO MEDICINE ENTER INTO EXCLUSIVE GLOBAL
LICENSE AGREEMENT FOR ISM3091, A POTENTIALLY BEST-IN-CLASS USP1
INHIBITOR
* EXELIXIS - INSILICO GRANTED CO WORLDWIDE LICENSE TO
DEVELOP,
COMMERCIALIZE ISM3091, OTHER USP1-TARGETING COMPOUNDS, FOR
UPFRONT PAYMENT OF $80 MILLION
* EXELIXIS INC - UPFRONT PAYMENT TO DEVELOP AND
COMMERCIALIZE
ISM3091, AND OTHER USP1-TARGETING COMPOUNDS TO INSILICO
ANTICIPATED IN Q3 2023
* EXELIXIS INC - INSILICO TO RECEIVE FUTURE DEVELOPMENT,
COMMERCIAL, AND SALES-BASED MILESTONE PAYMENTS, AS WELL AS
TIERED ROYALTIES ON NET SALES
Source text for Eikon: ID:nBw2g1nRWa
Further company coverage: EXEL.O
((reuters.briefs@thomsonreuters.com;))